Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component

Inclusion Criteria: * Subjects must have Chronic low back pain with high probability of a significant neuropathic component for 4 years or less (but no less than 3 months) * Subjects must be in generally good health, except for the presence of chronic low back pain with a neuropathic component. * Subjects must be literate and have the ability (unaided) to understand and use the interactive voice response system (IVRS), have daily access to a telephone or the internet in order to complete the IVRS assessments each day, perform telephone or web visits and complete all required assessments/forms Exclusion Criteria: * Subjects with past history of surgery for chronic low back pain. * Subjects with past history of failure on pregabalin treatment and/or intolerance associated with pregabalin or gabapentin. * Subjects with past history of intolerance associated with celecoxib or known hypersensitivity to celecoxib. * Patients with anticipated need for treatment with opioid analgesics, anti-epileptic medications, SNRI antidepressants or tricyclic antidepressants to alleviate pain during the course of the study. * Patients with chronic low back pain with a neuropathic component for more than 4 years. * Patients with neurologic disorders unrelated to low back pain that may confuse or confound the assessment of neuropathic pain (eg, primary or secondary nerve diseases). * Subjects considered at risk of suicide or self-harm based on investigator judgment and/or details of a risk assessment. * Use of prohibited medications in the absence of appropriate washout periods. * Patients with any severe pain associated with conditions other than chronic low back pain with a neuropathic component that may confound the assessment or self-evaluation of the pain due to chronic low back pain. * Patients with diabetes with poor glycemic control (HbA1c \>8%). * Patients with any clinically significant or unstable medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, would compromise participation in the study * Patients who have participated in any previous clinical trial for pregabalin or have participated in 2 or more previous clinical trials for pain related to chronic low back pain. * Patients who are likely to require surgery during the course of the study (except minor surgery, eg, for skin conditions) * Patients with a history of Substance Abuse as defined by DSM-IV-TR diagnostic criteria